Symbols

FLGT

Fulgent Genetics·NASDAQ

--(--)

FLGT fundamentals

FLGT Q4 2025 Earnings

Fulgent Genetics (FLGT) released its earnings on Feb 27, 2026: revenue was 83.34M (YoY +9.34%), missed estimates; EPS was 0.16 (YoY +300.00%), beat estimates.

Revenue / YoY

83.34M

+9.34%

EPS / YoY

0.16

+300.00%

Report date

Feb 27, 2026

FLGT Earnings Call Summary for Q4,2025

Revenue Resilience: FY2025 revenue grew 14% to $322.7M, driven by AI and digital pathology investments. 2026 guidance of $350M (+8.5%) reflects offset from Bako/StrataDx acquisitions despite 70% loss of largest customer volume.
AI-Driven Efficiency: 100% digital pathology adoption and 12 new AI modules to enhance pathologist productivity and reduce costs.
Therapeutic Momentum: FID-007 Phase II interim data expected at ASCO 2026, with Phase III启动计划在2027年上半年.
Financial Strength: $705.5M cash on hand, with $685M expected in 2026 (excluding tax refund delay).

Earnings

EPS

Revenue

Revenue & Expenses

FLGT has released its 2025 Q4 earnings report, with revenue of 83.34M, reflecting a YoY change of 9.34%, and net profit of -23.65M, showing a YoY change of -282.07%. The Sankey diagram below clearly presents FLGT's revenue sources and cost distribution.

Key Indicators

Fulgent Genetics (FLGT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Fulgent Genetics (FLGT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Fulgent Genetics (FLGT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Fulgent Genetics (FLGT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown